Scholarlink

Purpose <p>Post–hematopoietic stem cell transplantation (HSCT) graft-versus-host disease (GVHD) is associated with considerable healthcare costs, and impaired productivity may represent an additional financial burden. This analysis quantified GVHD-associated indirect costs of productivity loss by comparing work-related disability leave claims between patients with versus without GVHD.</p> Methods <p>Patients with claims for HSCT in the IBM<sup>®</sup> MarketScan Commercial Database and the Health and Productivity Management Database between 1/1/09–12/31/19 and associated short- or long-term disability claims were included.</p> Results <p>Of 354 patients with GVHD and 2629 patients without GVHD included in the analysis, a significantly greater percentage of patients with versus without GVHD had claims for short-term disability (GVHD, 43.5%; non-GVHD, 29.2%; <i>P</i> &lt; 0.001), long-term disability (GVHD, 19.9%; non-GVHD, 6.3%; <i>P</i> &lt; 0.001) or a combination of both (GVHD, 53.5%; non-GVHD, 30.5%; <i>P</i> &lt; 0.001). Disability leaves were, on average, longer for patients with GVHD versus without GVHD (short-term, 103 vs 59&#xa0;days, <i>P</i> &lt; 0.001; long-term, 120 vs 92&#xa0;days, <i>P</i> &lt; 0.001). Mean indirect costs of workdays lost due to disability leave were significantly higher among those with versus without GVHD (short-term, $13,180 vs&#xa0;$7504, <i>P</i> &lt; 0.001; long-term, $15,441 vs $11,850, <i>P</i> &lt; 0.001). Mean all-cause healthcare costs were significantly higher among those with versus without GVHD (short-term leave: $295,241 vs $95,937, <i>P</i> &lt; 0.001; long-term leave: $312,691 vs $94,285, <i>P</i> &lt; 0.001).</p> Conclusions <p>Most full-time employed patients with GVHD took disability leave, accounting for approximately half (127/261) of their total workdays, incurring higher indirect costs than patients without GVHD. Additionally, all-cause healthcare costs were threefold higher in patients with versus without GVHD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Extended disability leave and related costs among employed patients with versus without graft-versus-host disease following hematopoietic stem cell transplantation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月5日

查看全文
  • Jingbo Yu,
  • Valkal Bhatt,
  • John Galvin,
  • Krutika Jariwala-Parikh,
  • Ellen Thiel

摘要

Purpose

Post–hematopoietic stem cell transplantation (HSCT) graft-versus-host disease (GVHD) is associated with considerable healthcare costs, and impaired productivity may represent an additional financial burden. This analysis quantified GVHD-associated indirect costs of productivity loss by comparing work-related disability leave claims between patients with versus without GVHD.

Methods

Patients with claims for HSCT in the IBM® MarketScan Commercial Database and the Health and Productivity Management Database between 1/1/09–12/31/19 and associated short- or long-term disability claims were included.

Results

Of 354 patients with GVHD and 2629 patients without GVHD included in the analysis, a significantly greater percentage of patients with versus without GVHD had claims for short-term disability (GVHD, 43.5%; non-GVHD, 29.2%; P < 0.001), long-term disability (GVHD, 19.9%; non-GVHD, 6.3%; P < 0.001) or a combination of both (GVHD, 53.5%; non-GVHD, 30.5%; P < 0.001). Disability leaves were, on average, longer for patients with GVHD versus without GVHD (short-term, 103 vs 59 days, P < 0.001; long-term, 120 vs 92 days, P < 0.001). Mean indirect costs of workdays lost due to disability leave were significantly higher among those with versus without GVHD (short-term, $13,180 vs $7504, P < 0.001; long-term, $15,441 vs $11,850, P < 0.001). Mean all-cause healthcare costs were significantly higher among those with versus without GVHD (short-term leave: $295,241 vs $95,937, P < 0.001; long-term leave: $312,691 vs $94,285, P < 0.001).

Conclusions

Most full-time employed patients with GVHD took disability leave, accounting for approximately half (127/261) of their total workdays, incurring higher indirect costs than patients without GVHD. Additionally, all-cause healthcare costs were threefold higher in patients with versus without GVHD.